What are you looking to improve.
Browse by what you want, not by molecule names. Each peptide on Panya is tagged with the effects it produces (recovery, sleep, cognition, muscle growth, longevity, more) so you can land at the right entry without already knowing the chemical name.
Each page covers mechanism, typical practice, regulatory status by region, risks, citations, and vendor names worth your own diligence. We cover what users search for, regardless of evidence strength or risk band; missing pages are bugs, not features.
Showing 6 entries tagged metabolic + weight. See all
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome. Discovered in 2015. Animal data shows insulin-sensitisation and exercise-mimetic effects. Human trials are early; community practice is well ahead of...
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's disease. Phase 2 trials in obesity showed weight loss roughly twice that of historical anti-...
AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, specifically the C-terminal lipolytic region. Marketed for fat loss without the IGF-1 elevation or hyperglycaemia of full HGH. Failed Phase 2b in 20...
Retatrutide is Eli Lilly's triple agonist of the GLP-1, GIP, and glucagon receptors, currently in Phase 3 weight-loss trials. Phase 2 showed 24% body weight loss at 12 mg / 48 weeks, the strongest published GLP-1-class e...
Tesamorelin is an FDA-approved GHRH analog (Egrifta) for HIV-associated visceral lipodystrophy. Real prescription-routable peptide with multi-trial data showing 15-18% visceral adipose tissue reduction at 2 mg / 26 weeks...
Cagrilintide is Novo Nordisk's long-acting amylin / calcitonin receptor agonist, in Phase 3 (mostly via CagriSema, the combination with semaglutide). Different mechanism from GLP-1 / GIP; complementary rather than redund...